As2O3 oxidation by vitamin C: Cell culture studies

BioMetals

Volumn 25, Issue 1, 2012, Pages 103-113

  Pevec, Andreja Zelenik ^a   Šlejkovec, Zdenka ^a   Elteren, Johannes T Van ^b   Falnoga, Ingrid ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

Author keywords

Arsenic trioxide; Cell culture; Oxidation; Serum; Vitamin C

Indexed keywords

ALBUMIN; ARSENIC TRIOXIDE; ASCORBIC ACID; REACTIVE OXYGEN METABOLITE; RIBOFLAVIN; SELENOPROTEIN P; TRANSFERRIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ARSENOUS ACID DERIVATIVE; ORGANOARSENIC DERIVATIVE; OXIDE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOOXIDATION; CELL CULTURE; CULTURE MEDIUM; CYTOTOXICITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; NONHUMAN; OXIDATION; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION REACTION; SPECTROFLUOROMETRY; ANIMAL; CATTLE; CHEMISTRY; CULTURE TECHNIQUE; METHODOLOGY; TUMOR CELL LINE;

BOVINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ARSENICALS; ARSENITES; ASCORBIC ACID; CATTLE; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CULTURE MEDIA; OXIDATION-REDUCTION; OXIDES;

EID: 84861220137     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-011-9486-6     Document Type: Article

References (34)

1. Ahmad S, Kitchin KT, Cullen WR (2000) Arsenic species that cause release of iron from ferritin and generation of activated oxygen. Arch Biochem Biophys 382(2):195-202
2. Aposhian HV, Aposhian MM (2006) Arsenic toxicology: five questions. Chem Res Toxicol 19:1-15
3. Agency for Toxic Substances and Disease Registry (ATSDR) (2007) Toxicological profile for arsenic.US Department of Health and Human Services, Atlanta Berenson RJ, Matous J, Swift RA et al (2007) A Phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13:1762
4. Bertolero F, Pozzi G, Sabbioni E et al (1987) Cellular uptake and metabolic reduction of pentavalent to trivalent arsenic as determinants of cytotoxicity and morphological transformation. Carcinogenesis 8(6):803-808
5. Cell Therapeutics, Trisenox (2002) Cell Therapeutics Inc., London
6. Cephalon, Trisenox (arsenic trioxide) injection (2008), Prescribing information
7. Chen Q, Espey MG, Sun AY et al (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. PNAS 104(21):8749-8754
8. Chen Q, Espey MG, Su AY et al (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. PNAS 105(32): 11105-11109
9. Clement MV, Ramalingam J, Long LH et al (2001) The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid Redox Signal 3:157-163
10. Cui X, Kobayashi Y, Akashi M et al (2008) Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer. Curr Med Chem 15:2293-2304
11. Del Razo LM, Quintanilla-Vega B, Brambila-Colombres E et al (2001) Stress proteins induced by arsenic. Toxicol Appl Pharmacol 177:132-148
12. Dilda PJ, Hogg PJ (2007) Arsenical-based cancer drugs. Cancer Treat Rev 33:542-564
13. Drobna Z, Styblo M, Thomas DJ (2009) An overview of arsenic metabolism and toxicity. Curr Protoc Toxicol 42:4.31.1-4.31.6
14. Duarte TL, Almeida GM, Jones GDD (2007) Investigation of the role of extracellular H2O2 and transition metal ions in the genotoxic action of ascorbic acid in cell culture models. Toxicol Lett 170:57-65
15. Falnoga I, S ? lejkovec Z, Pucer A et al (2007) Arsenic metabolism in multiple myeloma and astrocytoma cells. Biol Trace Elem Res 116(1):5-28
16. Grad JM, Bahlis NJ, Reis I et al (2001) Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98(3):805-813
17. Grimm S, Marymont MA, Chandler J et al. (2008) Phase I trial of arsenic trioxide and temozolomide in combination with radiation therapy followed by adjuvant temozolomide for patients with high-grade gliomas. Neuro Oncol 10(5):759-915.
18. Grzelak A, Rychlik B, Bartosz G (2000) Reactive oxygen species are formed in cell culture media. Acta Biochim Polon 47:1197-1198
19. Grzelak A, Rychlik B, Bartosz G (2001) Light-dependent generation of reactive oxygen species in cell culture media. Free Radic Biol Med 30(12):1418-1425
20. Halliwell B, Gutteridge JMC (1999) Free radicals in biology and medicine, 3rd edn. Clarendon Press/Oxford University Press, Oxford/New York
21. Holmgren A, Lu J (2010) Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 396(1): 120-124
22. Karasavvas N, Carcamo JM, Stratis G et al (2005) Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 105:4004-4012
23. Lewinska A, Wnuk M, Slota E et al (2007) Total anti-oxidant capacity of cell culture media. Clin Exp Pharmacol Physiol 34:781-786
24. Lu J, Chew EH, Holmgren A (2007) Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104(30):12288-12293
25. Michel L, Dupuy A, Jean-Louis F et al (2003) Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol 121(4):881-893
26. Miller WH, Schipper HM, Lee JS et al (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903
27. Murgo AJ (2001) Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute. Cooperative research and development studies. Oncologist 6:2-28
28. Padayatty SJ, Levine M (2000) Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 19(4):423-425
29. Qazilbash MH, Saliba RM, Nieto Y et al (2008) Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transpl 14(12):1401-1407
30. S ? lejkovec Z, van Elteren JT, Woroniecka UD (2001) Underestimation of the total arsenic concentration by hydride generation techniques as a consequence of the incomplete mineralisation of arsenobetaine in acid digestion procedures. Anal Chim Acta 443:277-282
31. Van der Valk J, Brunner D, De Smet K et al (2010) Optimization of chemically defined cell culture media-replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro 24(4):1053-1063
32. van Elteren JT, Stibilj V, S ? lejkovec Z (2002) Speciation of inorganic arsenic in some bottled Slovene mineral watersusing HPLC-HGAFS and selective coprecipitation combined with FI-HGAFS. Water Res 36:2967-2974
33. Wondrak GT (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11(12):3013-3069
34. Yang YP, Liang ZQ, Gao B et al (2008) Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells. Acta Pharmacol Sin 29(1): 123-134